Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10640635 | 0.84 | EHMT2 (0.54) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL8708817 | 0.83 | EHMT2 (0.42) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL20069822 | 0.83 | HRH3 (0.42) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL8111459 | 0.81 | ALDH1A1 (0.44) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL15271041 | 0.80 | EHMT2 (0.50) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL15271518 | 0.80 | EHMT2 (0.50) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL21651940 | 0.80 | DDB1 (0.41) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL12949631 | 0.79 | EHMT2 (0.48) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL28455598 | 0.79 | EHMT2 (0.48) | EHMT2EHMT1APOBEC3GDDB1CRBN | |
| SCHEMBL15271760 | 0.79 | EHMT2 (0.48) | EHMT2EHMT1APOBEC3GDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
| EP-2316830-A2 | N-sulphonylated amino acid derivatives and their use as matriptase inhibitors | The Medicines Company (Leipzig) GmbH (DE) | 2011-05-04 | — | — | EP | disclosed |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-7772251-B2 | N-sulphonylated amino acid derivatives, method for the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772251-B2 | N-sulphonylated amino acid derivatives, method for the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| WO-2004101507-A2 | N-SULPHONYLATED AMINO ACID DERIVATIVES AND USE THEREOF AS MATRIPTASE INHIBITORS | CURACYTE CHEMISTRY GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | EHMT2 1789/4885EHMT1 1010/4885APOBEC3G 4531/4885 |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | EHMT2 2470/4885EHMT1 2128/4885APOBEC3G 1652/4885 |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | DNPEP, ANPEP, PEPD | EHMT2 2470/4885EHMT1 2128/4885APOBEC3G 1652/4885 |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | EHMT2 1789/4885EHMT1 1010/4885APOBEC3G 4531/4885 |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | EHMT2 1789/4885EHMT1 1010/4885APOBEC3G 4531/4885 |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | EHMT2 1789/4885EHMT1 1010/4885APOBEC3G 4531/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | EHMT2 1789/4885EHMT1 1010/4885APOBEC3G 4531/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | EHMT2 1789/4885EHMT1 1010/4885APOBEC3G 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.